GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy

Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01239251

Enrollment

Registered

2010-11-11

Start date

2010-11-30

Completion date

2011-11-30

Last updated

2015-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

GlowCap, adjuvant endocrine therapy

Brief summary

The purpose of this study is to test the ease of using a new device, called the GlowCap that reminds the patient to take their breast cancer hormone pill. The study will collect information about the experience with this device and what the patient thinks of its role in the daily pill taking routine.

Interventions

OTHERGlowCap device

Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* Early stage breast cancer patients taking adjuvant endocrine therapy (ie, tamoxifen, anastrozole, letrozole, exemestane). * Age ≥ 60 years * Must have broadband internet access at home (to enable the base for the system to communicate to the Vitality server). * Must have a landline or mobile phone

Exclusion criteria

* Non-English speaking patients

Design outcomes

Primary

Measure	Time frame	Description
Assess the usability of the GlowCap system by patients	2 years	\>60 years of age with early stage breast cancer.

Secondary

Measure	Time frame	Description
Measure the acceptance and satisfaction of the GlowCap reminder system	2 years	with respect to medication adherence in patients \>60 years with early stage breast cancer taking adjuvant endocrine therapy.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026